Frank Silver's Contact Details

Frank Silver's Company Details

Prometheon Pharma

Gainesville, FL, US • 5 - 9 Employees
Major Drugs

Prometheon Pharma has developed a transdermal platform technology called Topicon™, specifically formulated for the creation of drug patch products that allow for passive delivery across the skin of large molecule drugs such as recombinant human proteins and peptides that currently require daily administration by needle injections. We call our products TruePatch™ because they also don't use microneedles (euphemistically referred to as "protrusions"​ or "extensions"​) to puncture the skin surface. A TruePatch™ is applied to the skin just like other prescription patches or a medicated Band Aid. Prometheon is developing convenient, painless, affordable, and truly needle-free TruePatch™ products, such as a basal insulin TruePatch™ to treat diabetes and reverse prediabetes among increasing numbers of people, rich or poor, in every corner of the world. For the first time, we can talk about curing early type 2 diabetes and reversing the natural history of disease progression of prediabetes to established and irreversible type 2 diabetes. That's right. CURING and PREVENTING type 2 diabetes. Other TruePatch™ products may include insulin-like growth factor-1 (IGF-1) and human growth hormone (hGH) for the treatment of short stature in children and young adults as well as for hormone replacement in an increasing number of adults. We are partnering with other pharma companies who leverage on our platform technology to solve their drug delivery problems and advance their strategic goals. An industry-sponsored study of a Topicon™ Cyclosporin A topical therapy is underway for the treatment of inflammatory skin diseases and is expected to be completed in the fall of 2018. Prometheon is committed to finding simple and scalable biotechnology solutions for the complex health and social problems that threaten the public health and economy of every country in the world. For example, Prometheon is developing a novel class of anti-obesity drugs for the new millennium that increases the metabolism and breakdown of fat rather than the dismal historical failure of drugs associated with reducing appetite. Prometheon's Business Development Materials are available at https://app.box.com/s/79vbof3cfleecewpiwl4 1) Executive Summary (Download PDF file)2) 10- or 15-Slide Investor Pitch Decks (Download PPT file for animation and annotation)3) Financial Projection Calculator (Download Excel File for full functionality)